Filed by Onconetix, Inc.
Pursuant to Rule 425 under the Securities Act
of 1933
and deemed filed pursuant to Rule 14a-6(b)
under the Securities Exchange Act of 1934
Subject Company: Onconetix. Inc.
Commission File No.: 001-41294
Date: March 25, 2026
The following press release was published on March
25, 2026, by Onconetix, Inc. with respect to certain developments of Realbotix LLC.
Onconetix Highlights Realbotix’s Role
in Ericsson’s World-First 6G Trial Demonstration
Realbotix Humanoid Robot — Ericsson’s
First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s
U.S. Headquarters; Onconetix Has Entered into a Definitive Agreement to Acquire Realbotix
CINCINNATI, Ohio – March 25, 2026 –
Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) wishes to draw its shareholders’ attention
to a development reported by Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) (“Realbotix Corp.”), the parent
company of Realbotix LLC, the target of Onconetix’s previously announced pending acquisition.
Realbotix Corp. announced that one of its humanoid
robots, which had been purchased by Ericsson — Realbotix’s first enterprise client — was featured in Ericsson’s
recently completed live pre-standard 6G over-the-air (OTA) trial conducted at Ericsson’s U.S. headquarters in Plano, Texas. Onconetix
is sharing this development with its shareholders as it relates to the capabilities of Realbotix, the target of the pending acquisition.
During the demonstration, the Realbotix humanoid
robot served as a live robotics endpoint, transmitting video and interacting in real time over Ericsson’s test network. Ericsson’s
demonstration showcased how next-generation wireless networks can power AI robotics and real-time video streaming, highlighting the type
of high-speed, low-latency connectivity expected to support future AI-driven technologies.
The demonstration also highlighted Realbotix’s
AI-agnostic architecture, which enables its humanoid robots to integrate with a variety of AI systems, cloud platforms, and network environments.
This flexible approach is designed to allow Realbotix robots to operate across diverse ecosystems without dependence on any single AI
provider or software stack.
As previously announced on February 12, 2026,
Onconetix entered into a definitive share exchange agreement to acquire 100% of the issued and outstanding equity interests of Realbotix
LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined company is expected to trade on Nasdaq following
closing, which is anticipated to occur in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals,
and other closing conditions.
The full text of Realbotix Corp.’s press
release regarding the Ericsson trial, including the complete forward-looking statement disclaimer applicable to Realbotix Corp., is available
at www.realbotix.ai and on Realbotix Corp.’s SEDAR+ filing profile at www.sedarplus.ca.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage
biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®,
an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under
the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more
information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of
Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops
AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States,
Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information,
visit www.realbotix.ai.
* * * * * * *
Cautionary Note Regarding Forward–Looking
Information
Certain statements in this
communication are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be
identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,”
“expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated
benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current
expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially
from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change,
or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the
possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on
a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s
stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction;
the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that
the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals,
and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed
transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events;
the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price
before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does
not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s
Annual Report on Form 10-K filed with the SEC for the fiscal year ended December 31, 2025 (the “10-K”) and periodic reports
filed with the SEC on or after the date hereof. All of Onconetix’s forward-looking statements are expressly qualified by all such
risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.
Additional Information About the Proposed Transaction
and Where to Find It
In connection with the proposed
transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration
Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration
Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”),
and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the
Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix
to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus
or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT
DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS
REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND
WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND
RELATED MATTERS.
A copy of the Registration
Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be
obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or
Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings
either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective
directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed
transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s
transactions with related persons is set forth in the 10-K and definitive proxy statement for Onconetix’s 2025 special meeting of
stockholders, as filed with the SEC on November 10, 2025, and other documents that may be filed from time to time with the SEC. Additional
information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants
in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect
interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will
be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov
and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes
only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or
the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation
or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities
shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, or in a transaction
exempt from the registration requirements of the Securities Act of 1933.
